<p>一位非常看漲的分析師的舉動是導致 <strong>Summit Therapeutics</strong>（SMMT -3.62%）在週中股價健康上漲的消息。根據標準普爾全球市場情報公司彙編的數據，截至週五市場開盤前，該股的上漲幅度基本保持不變，此時其股價在本週已上漲近 8%。</p>
<h2>下一個癌症重磅藥物？</h2>
<p>這一消息的背後是 Evercore ISI 的分析師 Cory Kasimov，他在週三開始覆蓋 Summit 的股票。他堅定地站在公司的看漲陣營，給予其 “跑贏大盤”（即：買入）評級，目標價為每股 30 美元。這意味着相較於最近的收盤股價，潛在上漲幅度超過 56%。</p>
<p>這也是一種相當大膽的方式來啓動對 Summit 的覆蓋，因為這家生物技術公司的股票在過去一年中已經大幅上漲。投資者對公司的主導管線藥物——癌症治療藥物 ivonescimab 特別感到興奮，尤其是考慮到它在與 <strong>默克</strong> 的重磅藥物 Keytruda 的臨牀試驗中表現良好。</p>
<p>毫不奇怪，Kasimov 對 Summit 看漲的基礎是 ivonescimab，報告稱他認為該藥物的療效可能比許多人意識到的更強，並且看起來將為其開發者帶來豐厚的財務回報。</p>
<h2>比許多選擇更好的投資</h2>
<p>癌症是生物技術市場中持久受歡迎的治療領域，因此任何擁有有前景的腫瘤藥物的開發者都會引起關注和投資。儘管如此，考慮到最近在實驗室中的表現，Summit 的前景尤其令人期待，因此即使在當前高昂的價格下，它也顯得是一個值得投資的選擇。</p>

Summit治療

<p>Summit 治療的股票本週上漲了近 8%，這得益於 Evercore ISI 分析師 Cory Kasimov 的樂觀評級，他給予了 “跑贏大盤” 的評級，並設定了 30 美元的目標價，暗示超過 56% 的上漲潛力。投資者對該公司領先的癌症治療藥物 ivonescimab 持樂觀態度，該藥物在臨牀試驗中表現出色，相較於默克的 Keytruda 更具競爭力。Kasimov 認為 ivonescimab 的效果可能超出預期，使得 Summit 在生物科技領域的腫瘤市場中成為一個引人注目的投資選擇</p>

<p>A very bullish analyst move was the news generally responsible for <strong>Summit Therapeutics</strong>' (SMMT -3.62%) healthy mid-week stock price pop. That upward lift was largely holding as of Friday before market open, as according to data compiled by S&amp;P Global Market Intelligence Summit's share price had risen by almost 8% week to date at that point.</p>
<div class="lb-trans"><p>一位非常看漲的分析師的舉動是導致 <strong>Summit Therapeutics</strong>（SMMT -3.62%）在週中股價健康上漲的消息。根據標準普爾全球市場情報公司彙編的數據，截至週五市場開盤前，該股的上漲幅度基本保持不變，此時其股價在本週已上漲近 8%。</p>
</div><h2>The next cancer blockbuster drug?</h2>
<div class="lb-trans"><h2>下一個癌症重磅藥物？</h2>
</div><p>The person behind the news was Evercore ISI pundit Cory Kasimov, who on Wednesday launched coverage of Summit stock. He's quite firmly in the company's bull camp, as he initiated with an outperform (read: buy) recommendation at a price target of $30 per share. That suggests hefty potential upside of over 56% on the most recent closing stock price.</p>
<div class="lb-trans"><p>這一消息的背後是 Evercore ISI 的分析師 Cory Kasimov，他在週三開始覆蓋 Summit 的股票。他堅定地站在公司的看漲陣營，給予其 “跑贏大盤”（即：買入）評級，目標價為每股 30 美元。這意味着相較於最近的收盤股價，潛在上漲幅度超過 56%。</p>
</div><p>It is also quite a bold way to launch coverage of Summit, as the biotech company's stock has already soared well higher over the past year. Investors are most excited about the company's leading pipeline drug, cancer treatment ivonescimab, particularly given that it has performed well in clinical trials against <strong>Merck</strong>'s blockbuster drug Keytruda.</p>
<div class="lb-trans"><p>這也是一種相當大膽的方式來啓動對 Summit 的覆蓋，因為這家生物技術公司的股票在過去一年中已經大幅上漲。投資者對公司的主導管線藥物——癌症治療藥物 ivonescimab 特別感到興奮，尤其是考慮到它在與 <strong>默克</strong> 的重磅藥物 Keytruda 的臨牀試驗中表現良好。</p>
</div><p>Not surprisingly, Kasimov's bullishness on Summit is founded on ivonescimab, according to reports. He feels the drug might even prove to be more efficacious than many realize, and looks set to be very financially rewarding for its developer.</p>
<div class="lb-trans"><p>毫不奇怪，Kasimov 對 Summit 看漲的基礎是 ivonescimab，報告稱他認為該藥物的療效可能比許多人意識到的更強，並且看起來將為其開發者帶來豐厚的財務回報。</p>
</div><h2>A better bet than many</h2>
<div class="lb-trans"><h2>比許多選擇更好的投資</h2>
</div><p>Cancer is the enduringly popular therapeutic segment for the biotech market, so any developer with a promising oncology drug will attract notice and investment. That said, Summit's looks to be especially promising in light of that recent performance in the lab, and as such it feels like a worthy investment even at its current, lofty price.</p>
<div class="lb-trans"><p>癌症是生物技術市場中持久受歡迎的治療領域，因此任何擁有有前景的腫瘤藥物的開發者都會引起關注和投資。儘管如此，考慮到最近在實驗室中的表現，Summit 的前景尤其令人期待，因此即使在當前高昂的價格下，它也顯得是一個值得投資的選擇。</p>
</div>

為什麼 Summit Therapeutics 的股票本週表現出色